Literature DB >> 4006049

Combined therapeutic effects of an immunomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma.

D D Mickey.   

Abstract

Responses of bladder cancer in ACI rats to combination therapy with an immunomodulator, PSK, and an alkylating agent, carboquone, are reported. PSK is a protein-bound polysaccharide isolated from Basidiomycetes, and carboquone is the alkylating agent 2,5-bis(1-aziridinyl)-3-(2-hydroxy-1-methanoxyethyl)-6-methyl-p- benzoquinone carbonate, molecular weight 3,214. The immunomodulator, PSK, was shown to enhance the effectiveness of the chemotherapeutic agent, carboquone. The therapeutic effect of combination treatment was monitored by measuring growth rates of tumors transplanted SC and by measuring decreases in metastatic spread to lungs in tumor-bearing animals. Effects of PSK on host immunity were monitored by measuring serum levels of immunosuppressive substance.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006049     DOI: 10.1007/bf00257295

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  BCG in the management of superficial bladder cancer.

Authors:  S A Brosman
Journal:  Urology       Date:  1984-04       Impact factor: 2.649

2.  Levamisole immunotherapy of experimental transitional cell carcinoma.

Authors:  D L Lamm; G N Yee; D F Reichert; H M Radwin
Journal:  Invest Urol       Date:  1979-01

3.  Immunological evaluation of a streptococcal preparation (OK-432) in treatment of bladder carcinoma.

Authors:  S Kagawa; K Ogura; K Kurokawa; K Uyama
Journal:  J Urol       Date:  1979-10       Impact factor: 7.450

4.  Adjuvant immunotherapy in superficial bladder cancer.

Authors:  A Morales
Journal:  Natl Cancer Inst Monogr       Date:  1978-12

5.  Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer.

Authors:  M S Soloway
Journal:  Natl Cancer Inst Monogr       Date:  1978-12

6.  Application of human leucocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma.

Authors:  D Ikić; P Nola; Z Maricić; K Smudj; V Oresić; M Knezević; B Rode; D Jusić; E Soos
Journal:  Lancet       Date:  1981-05-09       Impact factor: 79.321

7.  Antigen characteristics of nitrosamine-induced urinary bladder cancer in rats.

Authors:  Y Hashimoto; H S Kitagawa
Journal:  Gan       Date:  1979-06

8.  Adjuvant long-term immunochemotherapy for squamous cell carcinoma of the thoracic esophagus.

Authors:  K Sugimachi; K Inokuchi; Y Okudaira; A Yaita; T Nakamura
Journal:  Am Surg       Date:  1980-10       Impact factor: 0.688

9.  Effect of combined use of anticancer drugs with a polysaccharide preparation, Krestin, on mouse leukemia P388.

Authors:  F Oh-hashi; T Kataoka; S Tsukagoshi
Journal:  Gan       Date:  1978-04

10.  Effect of intralesional and systemic BCG-application or a combined cyclophosphamide/BCG treatment on experimental bladder cancer.

Authors:  H D Adolphs; J Thiele; H Kiel
Journal:  Urol Res       Date:  1979-06-22
View more
  3 in total

1.  Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial.

Authors:  H Blomgren; I Näslund; P L Esposti; L Johansen; O Aaskoven
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Y-320, a novel immune-modulator, sensitizes multidrug-resistant tumors to chemotherapy.

Authors:  Jiawei Hong; Shilei Jing; Yanpeng Zhang; Ronggao Chen; Kwabena Gyabaah Owusu-Ansah; Bingjie Chen; Haiyang Xie; Lin Zhou; Shusen Zheng; Donghai Jiang
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

3.  In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer.

Authors:  Y Nio; T Shiraishi; M Tsubono; H Morimoto; C C Tseng; S Imai; T Tobe
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.